Lysosomal Disease Treatment Market, Global Outlook and Forecast 2022-2028

April 2022 | 64 pages | ID: L4D757661770EN
Market Monitor Global

Abstracts

Lysosomal disease treatment is a way to alleviate Lysosomal storage disease.

This report contains market size and forecasts of Lysosomal Disease Treatment in Global, including the following market information:

Global Lysosomal Disease Treatment Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Lysosomal Disease Treatment market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Hematopoietic Stem Cell Transplantation Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Lysosomal Disease Treatment include Astellas Pharma, Astrazeneca, Actelion Pharmaceuticals Ltd., Eli Lilly and Co., Merck & Co., Novo Nordisk A/S, Shire, Pfizer and Sanofi and etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Lysosomal Disease Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Lysosomal Disease Treatment Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Lysosomal Disease Treatment Market Segment Percentages, by Type, 2021 (%)

• Hematopoietic Stem Cell Transplantation
• Enzyme Replacement Therapy
• Substrate Reduction
• Chaperone Therapies

Global Lysosomal Disease Treatment Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Lysosomal Disease Treatment Market Segment Percentages, by Application, 2021 (%)

• Hospitals
• Clinics
• Stem Cell Transplant Center
• Research Organizations
• Others

Global Lysosomal Disease Treatment Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Lysosomal Disease Treatment Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Lysosomal Disease Treatment revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Lysosomal Disease Treatment revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Astellas Pharma
• Astrazeneca
• Actelion Pharmaceuticals Ltd.
• Eli Lilly and Co.
• Merck & Co.
• Novo Nordisk A/S
• Shire
• Pfizer
• Sanofi
• BioMarin

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Lysosomal Disease Treatment Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Application
1.3 Global Lysosomal Disease Treatment Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL LYSOSOMAL DISEASE TREATMENT OVERALL MARKET SIZE

2.1 Global Lysosomal Disease Treatment Market Size: 2021 VS 2028
2.2 Global Lysosomal Disease Treatment Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top Lysosomal Disease Treatment Players in Global Market
3.2 Top Global Lysosomal Disease Treatment Companies Ranked by Revenue
3.3 Global Lysosomal Disease Treatment Revenue by Companies
3.4 Top 3 and Top 5 Lysosomal Disease Treatment Companies in Global Market, by Revenue in 2021
3.5 Global Companies Lysosomal Disease Treatment Product Type
3.6 Tier 1, Tier 2 and Tier 3 Lysosomal Disease Treatment Players in Global Market
  3.6.1 List of Global Tier 1 Lysosomal Disease Treatment Companies
  3.6.2 List of Global Tier 2 and Tier 3 Lysosomal Disease Treatment Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 by Type - Global Lysosomal Disease Treatment Market Size Markets, 2021 & 2028
  4.1.2 Hematopoietic Stem Cell Transplantation
  4.1.3 Enzyme Replacement Therapy
  4.1.4 Substrate Reduction
  4.1.5 Chaperone Therapies
4.2 By Type - Global Lysosomal Disease Treatment Revenue & Forecasts
  4.2.1 By Type - Global Lysosomal Disease Treatment Revenue, 2017-2022
  4.2.2 By Type - Global Lysosomal Disease Treatment Revenue, 2023-2028
  4.2.3 By Type - Global Lysosomal Disease Treatment Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global Lysosomal Disease Treatment Market Size, 2021 & 2028
  5.1.2 Hospitals
  5.1.3 Clinics
  5.1.4 Stem Cell Transplant Center
  5.1.5 Research Organizations
  5.1.6 Others
5.2 By Application - Global Lysosomal Disease Treatment Revenue & Forecasts
  5.2.1 By Application - Global Lysosomal Disease Treatment Revenue, 2017-2022
  5.2.2 By Application - Global Lysosomal Disease Treatment Revenue, 2023-2028
  5.2.3 By Application - Global Lysosomal Disease Treatment Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Lysosomal Disease Treatment Market Size, 2021 & 2028
6.2 By Region - Global Lysosomal Disease Treatment Revenue & Forecasts
  6.2.1 By Region - Global Lysosomal Disease Treatment Revenue, 2017-2022
  6.2.2 By Region - Global Lysosomal Disease Treatment Revenue, 2023-2028
  6.2.3 By Region - Global Lysosomal Disease Treatment Revenue Market Share, 2017-2028
6.3 North America
  6.3.1 By Country - North America Lysosomal Disease Treatment Revenue, 2017-2028
  6.3.2 US Lysosomal Disease Treatment Market Size, 2017-2028
  6.3.3 Canada Lysosomal Disease Treatment Market Size, 2017-2028
  6.3.4 Mexico Lysosomal Disease Treatment Market Size, 2017-2028
6.4 Europe
  6.4.1 By Country - Europe Lysosomal Disease Treatment Revenue, 2017-2028
  6.4.2 Germany Lysosomal Disease Treatment Market Size, 2017-2028
  6.4.3 France Lysosomal Disease Treatment Market Size, 2017-2028
  6.4.4 U.K. Lysosomal Disease Treatment Market Size, 2017-2028
  6.4.5 Italy Lysosomal Disease Treatment Market Size, 2017-2028
  6.4.6 Russia Lysosomal Disease Treatment Market Size, 2017-2028
  6.4.7 Nordic Countries Lysosomal Disease Treatment Market Size, 2017-2028
  6.4.8 Benelux Lysosomal Disease Treatment Market Size, 2017-2028
6.5 Asia
  6.5.1 By Region - Asia Lysosomal Disease Treatment Revenue, 2017-2028
  6.5.2 China Lysosomal Disease Treatment Market Size, 2017-2028
  6.5.3 Japan Lysosomal Disease Treatment Market Size, 2017-2028
  6.5.4 South Korea Lysosomal Disease Treatment Market Size, 2017-2028
  6.5.5 Southeast Asia Lysosomal Disease Treatment Market Size, 2017-2028
  6.5.6 India Lysosomal Disease Treatment Market Size, 2017-2028
6.6 South America
  6.6.1 By Country - South America Lysosomal Disease Treatment Revenue, 2017-2028
  6.6.2 Brazil Lysosomal Disease Treatment Market Size, 2017-2028
  6.6.3 Argentina Lysosomal Disease Treatment Market Size, 2017-2028
6.7 Middle East & Africa
  6.7.1 By Country - Middle East & Africa Lysosomal Disease Treatment Revenue, 2017-2028
  6.7.2 Turkey Lysosomal Disease Treatment Market Size, 2017-2028
  6.7.3 Israel Lysosomal Disease Treatment Market Size, 2017-2028
  6.7.4 Saudi Arabia Lysosomal Disease Treatment Market Size, 2017-2028
  6.7.5 UAE Lysosomal Disease Treatment Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Astellas Pharma
  7.1.1 Astellas Pharma Corporate Summary
  7.1.2 Astellas Pharma Business Overview
  7.1.3 Astellas Pharma Lysosomal Disease Treatment Major Product Offerings
  7.1.4 Astellas Pharma Lysosomal Disease Treatment Revenue in Global Market (2017-2022)
  7.1.5 Astellas Pharma Key News
7.2 Astrazeneca
  7.2.1 Astrazeneca Corporate Summary
  7.2.2 Astrazeneca Business Overview
  7.2.3 Astrazeneca Lysosomal Disease Treatment Major Product Offerings
  7.2.4 Astrazeneca Lysosomal Disease Treatment Revenue in Global Market (2017-2022)
  7.2.5 Astrazeneca Key News
7.3 Actelion Pharmaceuticals Ltd.
  7.3.1 Actelion Pharmaceuticals Ltd. Corporate Summary
  7.3.2 Actelion Pharmaceuticals Ltd. Business Overview
  7.3.3 Actelion Pharmaceuticals Ltd. Lysosomal Disease Treatment Major Product Offerings
  7.3.4 Actelion Pharmaceuticals Ltd. Lysosomal Disease Treatment Revenue in Global Market (2017-2022)
  7.3.5 Actelion Pharmaceuticals Ltd. Key News
7.4 Eli Lilly and Co.
  7.4.1 Eli Lilly and Co. Corporate Summary
  7.4.2 Eli Lilly and Co. Business Overview
  7.4.3 Eli Lilly and Co. Lysosomal Disease Treatment Major Product Offerings
  7.4.4 Eli Lilly and Co. Lysosomal Disease Treatment Revenue in Global Market (2017-2022)
  7.4.5 Eli Lilly and Co. Key News
7.5 Merck & Co.
  7.5.1 Merck & Co. Corporate Summary
  7.5.2 Merck & Co. Business Overview
  7.5.3 Merck & Co. Lysosomal Disease Treatment Major Product Offerings
  7.5.4 Merck & Co. Lysosomal Disease Treatment Revenue in Global Market (2017-2022)
  7.5.5 Merck & Co. Key News
7.6 Novo Nordisk A/S
  7.6.1 Novo Nordisk A/S Corporate Summary
  7.6.2 Novo Nordisk A/S Business Overview
  7.6.3 Novo Nordisk A/S Lysosomal Disease Treatment Major Product Offerings
  7.6.4 Novo Nordisk A/S Lysosomal Disease Treatment Revenue in Global Market (2017-2022)
  7.6.5 Novo Nordisk A/S Key News
7.7 Shire
  7.7.1 Shire Corporate Summary
  7.7.2 Shire Business Overview
  7.7.3 Shire Lysosomal Disease Treatment Major Product Offerings
  7.7.4 Shire Lysosomal Disease Treatment Revenue in Global Market (2017-2022)
  7.7.5 Shire Key News
7.8 Pfizer
  7.8.1 Pfizer Corporate Summary
  7.8.2 Pfizer Business Overview
  7.8.3 Pfizer Lysosomal Disease Treatment Major Product Offerings
  7.8.4 Pfizer Lysosomal Disease Treatment Revenue in Global Market (2017-2022)
  7.8.5 Pfizer Key News
7.9 Sanofi
  7.9.1 Sanofi Corporate Summary
  7.9.2 Sanofi Business Overview
  7.9.3 Sanofi Lysosomal Disease Treatment Major Product Offerings
  7.9.4 Sanofi Lysosomal Disease Treatment Revenue in Global Market (2017-2022)
  7.9.5 Sanofi Key News
7.10 BioMarin
  7.10.1 BioMarin Corporate Summary
  7.10.2 BioMarin Business Overview
  7.10.3 BioMarin Lysosomal Disease Treatment Major Product Offerings
  7.10.4 BioMarin Lysosomal Disease Treatment Revenue in Global Market (2017-2022)
  7.10.5 BioMarin Key News

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Lysosomal Disease Treatment Market Opportunities & Trends in Global Market
Table 2. Lysosomal Disease Treatment Market Drivers in Global Market
Table 3. Lysosomal Disease Treatment Market Restraints in Global Market
Table 4. Key Players of Lysosomal Disease Treatment in Global Market
Table 5. Top Lysosomal Disease Treatment Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Lysosomal Disease Treatment Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Lysosomal Disease Treatment Revenue Share by Companies, 2017-2022
Table 8. Global Companies Lysosomal Disease Treatment Product Type
Table 9. List of Global Tier 1 Lysosomal Disease Treatment Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Lysosomal Disease Treatment Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Lysosomal Disease Treatment Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Lysosomal Disease Treatment Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Lysosomal Disease Treatment Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Lysosomal Disease Treatment Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Lysosomal Disease Treatment Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Lysosomal Disease Treatment Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Lysosomal Disease Treatment Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Lysosomal Disease Treatment Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Lysosomal Disease Treatment Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Lysosomal Disease Treatment Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Lysosomal Disease Treatment Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Lysosomal Disease Treatment Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Lysosomal Disease Treatment Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Lysosomal Disease Treatment Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Lysosomal Disease Treatment Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Lysosomal Disease Treatment Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Lysosomal Disease Treatment Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Lysosomal Disease Treatment Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Lysosomal Disease Treatment Revenue, (US$, Mn), 2023-2028
Table 30. Astellas Pharma Corporate Summary
Table 31. Astellas Pharma Lysosomal Disease Treatment Product Offerings
Table 32. Astellas Pharma Lysosomal Disease Treatment Revenue (US$, Mn), (2017-2022)
Table 33. Astrazeneca Corporate Summary
Table 34. Astrazeneca Lysosomal Disease Treatment Product Offerings
Table 35. Astrazeneca Lysosomal Disease Treatment Revenue (US$, Mn), (2017-2022)
Table 36. Actelion Pharmaceuticals Ltd. Corporate Summary
Table 37. Actelion Pharmaceuticals Ltd. Lysosomal Disease Treatment Product Offerings
Table 38. Actelion Pharmaceuticals Ltd. Lysosomal Disease Treatment Revenue (US$, Mn), (2017-2022)
Table 39. Eli Lilly and Co. Corporate Summary
Table 40. Eli Lilly and Co. Lysosomal Disease Treatment Product Offerings
Table 41. Eli Lilly and Co. Lysosomal Disease Treatment Revenue (US$, Mn), (2017-2022)
Table 42. Merck & Co. Corporate Summary
Table 43. Merck & Co. Lysosomal Disease Treatment Product Offerings
Table 44. Merck & Co. Lysosomal Disease Treatment Revenue (US$, Mn), (2017-2022)
Table 45. Novo Nordisk A/S Corporate Summary
Table 46. Novo Nordisk A/S Lysosomal Disease Treatment Product Offerings
Table 47. Novo Nordisk A/S Lysosomal Disease Treatment Revenue (US$, Mn), (2017-2022)
Table 48. Shire Corporate Summary
Table 49. Shire Lysosomal Disease Treatment Product Offerings
Table 50. Shire Lysosomal Disease Treatment Revenue (US$, Mn), (2017-2022)
Table 51. Pfizer Corporate Summary
Table 52. Pfizer Lysosomal Disease Treatment Product Offerings
Table 53. Pfizer Lysosomal Disease Treatment Revenue (US$, Mn), (2017-2022)
Table 54. Sanofi Corporate Summary
Table 55. Sanofi Lysosomal Disease Treatment Product Offerings
Table 56. Sanofi Lysosomal Disease Treatment Revenue (US$, Mn), (2017-2022)
Table 57. BioMarin Corporate Summary
Table 58. BioMarin Lysosomal Disease Treatment Product Offerings
Table 59. BioMarin Lysosomal Disease Treatment Revenue (US$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. Lysosomal Disease Treatment Segment by Type in 2021
Figure 2. Lysosomal Disease Treatment Segment by Application in 2021
Figure 3. Global Lysosomal Disease Treatment Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Lysosomal Disease Treatment Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Lysosomal Disease Treatment Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Lysosomal Disease Treatment Revenue in 2021
Figure 8. By Type - Global Lysosomal Disease Treatment Revenue Market Share, 2017-2028
Figure 9. By Application - Global Lysosomal Disease Treatment Revenue Market Share, 2017-2028
Figure 10. By Region - Global Lysosomal Disease Treatment Revenue Market Share, 2017-2028
Figure 11. By Country - North America Lysosomal Disease Treatment Revenue Market Share, 2017-2028
Figure 12. US Lysosomal Disease Treatment Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Lysosomal Disease Treatment Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Lysosomal Disease Treatment Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Lysosomal Disease Treatment Revenue Market Share, 2017-2028
Figure 16. Germany Lysosomal Disease Treatment Revenue, (US$, Mn), 2017-2028
Figure 17. France Lysosomal Disease Treatment Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Lysosomal Disease Treatment Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Lysosomal Disease Treatment Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Lysosomal Disease Treatment Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Lysosomal Disease Treatment Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Lysosomal Disease Treatment Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Lysosomal Disease Treatment Revenue Market Share, 2017-2028
Figure 24. China Lysosomal Disease Treatment Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Lysosomal Disease Treatment Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Lysosomal Disease Treatment Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Lysosomal Disease Treatment Revenue, (US$, Mn), 2017-2028
Figure 28. India Lysosomal Disease Treatment Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Lysosomal Disease Treatment Revenue Market Share, 2017-2028
Figure 30. Brazil Lysosomal Disease Treatment Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Lysosomal Disease Treatment Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Lysosomal Disease Treatment Revenue Market Share, 2017-2028
Figure 33. Turkey Lysosomal Disease Treatment Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Lysosomal Disease Treatment Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Lysosomal Disease Treatment Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Lysosomal Disease Treatment Revenue, (US$, Mn), 2017-2028
Figure 37. Astellas Pharma Lysosomal Disease Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Astrazeneca Lysosomal Disease Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Actelion Pharmaceuticals Ltd. Lysosomal Disease Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Eli Lilly and Co. Lysosomal Disease Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Merck & Co. Lysosomal Disease Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Novo Nordisk A/S Lysosomal Disease Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Shire Lysosomal Disease Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Pfizer Lysosomal Disease Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. Sanofi Lysosomal Disease Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 46. BioMarin Lysosomal Disease Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)